Search
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalLunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … It is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing
Lumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigationalLumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). … [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation.
Rimantadine
go.drugbank.com/drugs/DB00478ApprovedAn RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Tocainide
go.drugbank.com/drugs/DB01056ApprovedWithdrawnAn antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IbSynonyms: 2-amino-N-(2,6-dimethylphenyl)propanamide, 2-Amino-N-(2,6-dimethylphenyl)propionamidFruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalThis approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … Although [bevacizumab] is successful in sustaining target inhibition, mandatory intravenous dosing, immunogenicity, and the potential to induce autoimmune diseases hinder its clinical application.
Tetrabenazine
go.drugbank.com/drugs/DB04844ApprovedA drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. … It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag is currently in phase III development in various European countries including Austria, Belgium, Germany, and the UK [A36730]. … In September 2015, lusutrombopag received its first global approval in Japan to reduce the need for platelet transfusion in adults with chronic liver disease and thrombocytopenia who are schedule to undergo
Prezatide
go.drugbank.com/drugs/DB11296ApprovedIt is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated. … Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions [A19503]. Prezatide is used in cosmetic products for the skin and hair.
Liotrix
go.drugbank.com/drugs/DB01583ApprovedIn fact, administration of T3 may result in supratherapeutic levels of T3. … It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% of serum T3 is derived from deiodination of T4 in peripheral tissues.
Cipaglucosidase alfa
go.drugbank.com/drugs/DB16708ApprovedInvestigationalin Pompe disease. … by a deficiency in GAA.